Scarica l'app Stockscreener
1,122.50
0.61%
-6.85
Dopo l'orario di chiusura:
1121.90
-0.60
-0.05%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Lilly Eli Co Borsa (LLY) Ultime notizie
3 Under-the-Radar Stocks to Buy and Hold for a Decade - The Motley Fool
Eli Lilly Broadens Oncology Story With Jaypirca CLL Win And JAK2 Advance - simplywall.st
Lilly bet $2.3B on a Cambridge biotech and its first clinical trial just showed why - MassLive
GLP-1s, Eli Lilly to upgrade Alabama economy - The Business Journals
Early trial data points to Eli Lilly's AJ1-11095 in myelofibrosis - AD HOC NEWS
Why Eli Lilly's Oral Medicine Is Turning Heads? - Kalkine Media
Lilly Backs Abridge to Bring Ambient AI Into Clinical Trial Recruitment - AIM Media House
Eli Lilly Eyes Label Expansion For Leukemia Drug - Benzinga
Lilly Sues Cipla to Block Copy of Breast Cancer Drug Verzenio - Bloomberg Law News
BMO reiterates Outperform on Eli Lilly stock, cites JAK2i data - Investing.com
BMO Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,300 - Moomoo
Is LLY Overvalued? DCF Says Worth $762 - GuruFocus
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,400 - Moomoo
Eli Lilly JAK2 Data Highlights Pipeline Beyond Obesity And Valuation Upside - Yahoo Finance
Eli Lilly (LLY) Reports Promising Phase 1 Study Results for New Myelofibrosis Treatment - GuruFocus
Eli Lilly (LLY) Reports Promising Phase 3 Trial Results for Jayp - GuruFocus
3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow - AOL.com
Eli Lilly & Co Shs Cert Deposito Arg Repr 0.14285714 Shs Trade Ideas — BCBA:LLY.CI - TradingView
Eli Lilly & Co. Stock (US5324571083): Weekly technical picture in focus - AD HOC NEWS
Lilly's Jaypirca significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL - Investing News Network
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL - investor.lilly.com
Eli Lilly & Co. Stock (US5324571083): Novo Nordisk peer check keeps obesity drug leader in focus - AD HOC NEWS
Is Eli Lilly (LLY) One Of The Most Profitable Blue Chip Stocks To Buy According To Hedge Funds? - Insider Monkey
Lilly trial drug cuts spleen size, symptoms in myelofibrosis - Stock Titan
Jim Cramer Wasn’t Selling Eli Lilly (LLY) - Insider Monkey
Abridge Secures Strategic Investment From Eli Lilly, Expands AI Platform Into Payer and Research Workflows - Digital Health News
LLY News | ELI LILLY & CO (NYSE:LLY) - ChartMill
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance Australia
Eli Lilly & Co. stock underperforms Friday when compared to competitors - MarketWatch
Is Eli Lilly's Growth Story Still Gaining Strength? - Kalkine Media
Eli Lilly’s Abridge Bet Links Healthcare AI To Valuation And Growth - Yahoo Finance
The Catch Hiding In Eli Lilly Stock’s Growth Story - Trefis
Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About - The Globe and Mail
Eli Lilly (LLY) Moves to Enforce 340B Claims Data Reporting Compliance - Insider Monkey
Forget Eli Lilly and Company: As June Volatility Rocks High-Flyers, This Stock Is a No-Brainer Buy - Yahoo Finance
Prometheus raises $12 billion in capital for artificial engineers - statnews.com
Goldman Sachs Maintains a Buy Rating on Eli Lilly (LLY), Cites Encouraging Obesity Treatment Pipeline - Insider Monkey
Eli Lilly and Company $LLY is Xponance LLC's 10th Largest Position - MarketBeat
American Express, Live Nation And A Health Care Stock: CNBC's 'Final Trades' - Benzinga
Eli Lilly donates $50,000 to Kenosha YMCA for teen services - Kenosha News
Polen Capital Management LLC Lowers Position in Eli Lilly and Company $LLY - MarketBeat
Kovack Advisors Inc. Purchases 3,506 Shares of Eli Lilly and Company $LLY - MarketBeat
IFM Investors Pty Ltd Boosts Stock Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Stock Position Boosted by Parnassus Investments LLC - MarketBeat
Nuveen LLC Raises Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
The Catch Hiding In Eli Lilly Stock's Growth Story - Trefis
Eli Lilly and Company (LLY)’s Foundayo Hits New Weight Loss Milestone among Menopause Ladies - Insider Monkey
Eli Lilly Stock Outlook 2026: The Retatrutide Upgrade Cycle - EBC Financial Group
Insider Sell: Ilya Yuffa Sells 2,500 Shares of Eli Lilly and Co (LLY) - GuruFocus
Eli Lilly and Company (NYSE:LLY) Shares Up 2.2%What's Next? - MarketBeat
Eli Lilly Insider Sold Shares Worth $2,876,925, According to a Recent SEC Filing - Moomoo
Eli Lilly & Co. stock outperforms competitors on strong trading day - MarketWatch
Eli Lilly (NYSE: LLY) EVP Ilya Yuffa sells 2,500 shares in 10b5-1 trade - Stock Titan
Abridge inks deals with Nvidia and Lilly - statnews.com
Abridge is becoming the operating system for medicine after landing Eli Lilly equity and a clinical foundation model deal with NVIDIA - Startup Fortune
Eli Lilly vs Novo Nordisk: The Battle for Obesity Drug Supremacy - Yahoo Finance
Abridge wants to be the operating system for medicine—and NVIDIA and Eli Lilly are helping build it - Fortune
Accelerating Speed to Patient: A Conversation With Eli Lilly’s Sarah O’Keeffe - Pharmaceutical Executive
Abridge picks up strategic investment from Eli Lilly, expands payer, research workflows - Fierce Healthcare
Eli Lilly (LLY) Faces Coverage Challenges for GLP-1 Weight Loss Drugs - GuruFocus
Eli Lilly (LLY) Stock Climbs on Explosive Weight Loss Drug Demand and 56% Sales Growth - FXLeaders
AlzeCure inks Alzheimer's deal with Eli Lilly - BioXconomy
Eli Lilly & Co (NYSE:LLY): An Affordable Growth Opportunity in the Pharmaceutical Sector - ChartMill
0.20%
0.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):